157 related articles for article (PubMed ID: 24931803)
1. Current clinical presentation and treatment of localized prostate cancer in the United States.
Mahmood U; Levy LB; Nguyen PL; Lee AK; Kuban DA; Hoffman KE
J Urol; 2014 Dec; 192(6):1650-6. PubMed ID: 24931803
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).
Schymura MJ; Kahn AR; German RR; Hsieh MC; Cress RD; Finch JL; Fulton JP; Shen T; Stuckart E
BMC Cancer; 2010 Apr; 10():152. PubMed ID: 20403178
[TBL] [Abstract][Full Text] [Related]
3. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
[TBL] [Abstract][Full Text] [Related]
4. A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer.
Wong AT; Safdieh JJ; Rineer J; Weiner J; Schwartz D; Schreiber D
Int Urol Nephrol; 2015 Oct; 47(10):1629-34. PubMed ID: 26329748
[TBL] [Abstract][Full Text] [Related]
5. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
6. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.
Wenger H; Weiner AB; Razmaria A; Paner GP; Eggener SE
Urol Oncol; 2017 Jan; 35(1):31.e1-31.e6. PubMed ID: 27692833
[TBL] [Abstract][Full Text] [Related]
7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
8. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
9. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
[TBL] [Abstract][Full Text] [Related]
10. Physician variation in management of low-risk prostate cancer: a population-based cohort study.
Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD
JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650
[TBL] [Abstract][Full Text] [Related]
11. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
12. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
13. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
14. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
[TBL] [Abstract][Full Text] [Related]
15. Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.
Narang AK; Gergis C; Robertson SP; He P; Ram AN; McNutt TR; Griffith E; DeWeese TA; Honig S; Singh H; Song DY; Tran PT; DeWeese TL
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):254-62. PubMed ID: 26853334
[TBL] [Abstract][Full Text] [Related]
16. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
17. Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States.
Mahase SS; D'Angelo D; Kang J; Hu JC; Barbieri CE; Nagar H
JAMA Netw Open; 2020 Feb; 3(2):e1920471. PubMed ID: 32022878
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Mazzone E; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2018 Aug; 1(3):215-222. PubMed ID: 31102624
[TBL] [Abstract][Full Text] [Related]
19. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
Wilt TJ
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
[TBL] [Abstract][Full Text] [Related]
20. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]